Reauthorization of MDUFA: What It Means for Jobs, Innovation and Patients

Panel I

Dr. Jeffrey Shuren

• Director
• Center for Devices and Radiological Health (CDRH)
• Food and Drug Administration (FDA)
• Witness Testimony (Truth in Testimony)

Panel II

David Perez

• President and Chief Executive Officer
• Terumo BCT
• Witness Testimony (Truth in Testimony)

Elisabeth M. George

• Vice President, Global Government Affairs, Regulations and Standards
• Philips Healthcare
• Witness Testimony (Truth in Testimony)

Ralph Hall, J.D.

• Distinguished Professor and Practitioner
• University of Minnesota Law School
• Witness Statement (Truth in Testimony)

Ross Jaffe, M.D.

• Managing Director
• Versant Ventures
• Witness Statement (Truth in Testimony)

Aaron S. Kesselheim, M.D., J.D., M.P.H.

• Assistant Professor of Medicine at Harvard Medical School
• Division of Pharmacoepidemiology and Pharmacoeconomics
• Brigham and Women's Hospital
• Witness Testimony (Truth in Testimony)

Art Sedrakyan, M.D., Ph.D.

• Associate Professor
• Director, Patient-Centered Comparative Effectiveness Program
• Weill Cornell Medical College and New York Presbyterian Hospital
• Witness Testimony (Truth in Testimony)

Lisa Swirsky

• Senior Policy Analyst
• Consumers Union
• Witness Testimony (Truth in Testimony)

Mr. Jim Shull

• Browns Mills, NJ
• Witness Testimony (Truth in Testimony)